Clinical Significance of Annexin A1 Expression in Breast Cancer.
10.4048/jbc.2011.14.4.262
- Author:
Cha Kyong YOM
1
;
Wonshik HAN
;
Sung Won KIM
;
Hee Sung KIM
;
Hee Chul SHIN
;
Ji Na CHANG
;
Minyoung KOO
;
Dong Young NOH
;
Byung In MOON
Author Information
1. Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Publication Type:Original Article
- Keywords:
Annexin A1;
Breast neoplasms
- MeSH:
Annexin A1;
Biopsy, Large-Core Needle;
Breast;
Breast Diseases;
Breast Neoplasms;
Carcinoma, Intraductal, Noninfiltrating;
Humans;
Multivariate Analysis;
Neoplasm Staging
- From:Journal of Breast Cancer
2011;14(4):262-268
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The expression of Annexin A1 (ANXA1) is known to be reduced in human breast cancer; however, the role of ANXA1 expression in the development of breast cancer remains unclear. In this study, we determined the relationship between the expression features of ANXA1 and the prognostic factors of breast cancer. METHODS: Human breast tissues were obtained from patients specimens who had undergone breast surgery or core needle biopsies. The patterns of ANXA1 expression were analyzed by immunohistochemical staining in relation to histopathological diagnosis, clinical characteristics and outcomes. RESULTS: One hundred eighty-two cases were included and the mean age of the patients was 46.34 +/- 11.5 years. A significant loss of ANXA1 expression was noted in both ductal carcinoma in situ (DCIS) and invasive carcinomas compared to normal breast tissues (p<0.001) and benign breast diseases (p<0.001). There was a significant alteration in ANXA1 expression according to hormone receptor status (p<0.001), cancer intrinsic type (p<0.001), and nuclear grade (p=0.004) in invasive cancer. In a univariate analysis, ANXA1 positivity tended to be related with poor breast cancer-related survival (p=0.062); however, the same results was not realized in multivariate results (p=0.406). HER2 overexpression and TNM staging were significantly associated with relapse-free survivals (RFS) in the multivariate analysis (p=0.037, p=0.048, respectively). In particular, in node-positive patients (p=0.048), HER2 overexpressed patients (p=0.013), and non-triple negative breast cancer patients (p=0.002), ANXA1 overexpression was correlated with poor RFS. CONCLUSION: Although significant loss of ANXA1 expression was noted in breast cancer including DCIS and invasive carcinoma, in cases of invasive cancer, overexpression of ANXA1 was related to unfavorable prognostic factors. And these results imply that ANXA1 plays dualistic roles and is involved in variable mechanisms related to cancer development and progression.
